{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:13:31Z","timestamp":1778026411565,"version":"3.51.4"},"reference-count":18,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004599","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004599","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.cllc.2026.03.004","type":"journal-article","created":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T16:00:57Z","timestamp":1773676857000},"page":"91-96","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of Consolidation Durvalumab on Local Control Following Chemoradiotherapy for Non\u2013Small Cell Lung Cancer"],"prefix":"10.1016","volume":"27","author":[{"given":"Adel","family":"Zakharia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Bodner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Balazs","family":"Halmos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madhur","family":"Garg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rasim","family":"Gucalp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haiying","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brendon","family":"Stiles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9593-513X","authenticated-orcid":false,"given":"Nitin","family":"Ohri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.cllc.2026.03.004_bib0001","doi-asserted-by":"crossref","first-page":"506","DOI":"10.21037\/tlcr.2020.03.40","article-title":"Epidemiology of stage III lung cancer: frequency, diagnostic characteristics, and survival","volume":"10","author":"Casal-Mouri\u00f1o","year":"2021","journal-title":"Transl Lung Cancer Res"},{"issue":"1","key":"10.1016\/j.cllc.2026.03.004_bib0002","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.lungcan.2014.10.016","article-title":"Pre-treatment FDG-PET predicts the site of in-field progression following concurrent chemoradiotherapy for stage III non-small cell lung cancer","volume":"87","author":"Ohri","year":"2015","journal-title":"Lung Cancer"},{"issue":"2","key":"10.1016\/j.cllc.2026.03.004_bib0003","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.radonc.2017.08.007","article-title":"Mid-radiotherapy PET\/CT for prognostication and detection of early progression in patients with stage III non-small cell lung cancer","volume":"125","author":"Gensheimer","year":"2017","journal-title":"Radiother Oncol"},{"issue":"4","key":"10.1016\/j.cllc.2026.03.004_bib0004","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/0360-3016(94)00475-Z","article-title":"Radiation dose-response of human tumors","volume":"32","author":"Okunieff","year":"1995","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"10.1016\/j.cllc.2026.03.004_bib0005","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S0360-3016(01)02659-1","article-title":"Uncertainties in model-based outcome predictions for treatment planning","volume":"51","author":"Deasy","year":"2001","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"10.1016\/j.cllc.2026.03.004_bib0006","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.ijrobp.2025.01.005","article-title":"Randomized evaluation of the PET-adjusted IMRT for NSCLC trial (REPAINT)","volume":"122","author":"Ohri","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"10.1016\/j.cllc.2026.03.004_bib0007","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.ijrobp.2017.10.032","article-title":"Positron emission tomography\u2013adjusted intensity modulated radiation therapy for locally advanced non-small cell lung cancer","volume":"102","author":"Ohri","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.cllc.2026.03.004_bib0008","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/s13014-020-01546-y","article-title":"Predicting per-lesion local recurrence in locally advanced non-small cell lung cancer following definitive radiation therapy using pre- and mid-treatment metabolic tumor volume","volume":"15","author":"Binkley","year":"2020","journal-title":"Radiat Oncol"},{"issue":"24","key":"10.1016\/j.cllc.2026.03.004_bib0009","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa1809697","article-title":"Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC","volume":"379","author":"Antonia","year":"2018","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.cllc.2026.03.004_bib0010","first-page":"953","article-title":"Pattern of failure following chemoradiation for locally advanced non-small-cell lung cancer","volume":"30","author":"Nguyen","year":"2010","journal-title":"Anticancer Res"},{"issue":"1","key":"10.1016\/j.cllc.2026.03.004_bib0011","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1093\/jrr\/rrac057","article-title":"Recurrence patterns and progression-free survival after chemoradiotherapy with or without consolidation durvalumab for stage III non-small cell lung cancer","volume":"64","author":"Kishi","year":"2023","journal-title":"J Radiat Res"},{"key":"10.1016\/j.cllc.2026.03.004_bib0012","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/s13014-020-01590-8","article-title":"Pattern-of-failure and salvage treatment analysis after chemoradiotherapy for inoperable stage III non-small cell lung cancer","volume":"15","author":"Taugner","year":"2020","journal-title":"Radiat Oncol"},{"issue":"1 Suppl","key":"10.1016\/j.cllc.2026.03.004_bib0013","first-page":"LBA6","article-title":"Patterns of disease progression with durvalumab in stage III non-small cell lung cancer (PACIFIC)","volume":"105","author":"Rimner","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"7","key":"10.1016\/j.cllc.2026.03.004_bib0014","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1200\/JCO.19.01162","article-title":"Long-term results of NRG Oncology RTOG 0617: standard- versus high-dose chemoradiotherapy with or without cetuximab for unresectable stage III non-small-cell lung cancer","volume":"38","author":"Bradley","year":"2020","journal-title":"J Clin Oncol"},{"issue":"33","key":"10.1016\/j.cllc.2026.03.004_bib0015","doi-asserted-by":"crossref","first-page":"3935","DOI":"10.1200\/JCO.24.00022","article-title":"Primary results of NRG-RTOG1106\/ECOG-ACRIN 6697: a randomized phase II trial of individualized adaptive (chemo)radiotherapy using midtreatment 18F-FDG PET\/CT in stage III non-small cell lung cancer","volume":"42","author":"Kong","year":"2024","journal-title":"J Clin Oncol"},{"issue":"9687","key":"10.1016\/j.cllc.2026.03.004_bib0016","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S0140-6736(09)60737-6","article-title":"Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomized controlled trial","volume":"374","author":"Albain","year":"2009","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.cllc.2026.03.004_bib0017","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3816\/CLC.2000.n.020","article-title":"Randomized trial of surgery versus radiotherapy in patients with stage IIIA (N2) non-small-cell lung cancer after a response to induction chemotherapy: EORTC 08941","volume":"2","author":"Splinter","year":"2000","journal-title":"Clin Lung Cancer"},{"issue":"21","key":"10.1016\/j.cllc.2026.03.004_bib0018","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","article-title":"CheckMate 816 investigators. Neoadjuvant nivolumab plus chemotherapy in resectable non-small-cell lung cancer","volume":"386","author":"Forde","year":"2022","journal-title":"N Engl J Med"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730426000380?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730426000380?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T23:55:58Z","timestamp":1778025358000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730426000380"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":18,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S1525730426000380"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2026.03.004","relation":{},"ISSN":["1525-7304"],"issn-type":[{"value":"1525-7304","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of Consolidation Durvalumab on Local Control Following Chemoradiotherapy for Non\u2013Small Cell Lung Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2026.03.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}